Alnylam Pharmaceuticals, Inc. (ALNY)
266.11
+1.61
(+0.61%)
USD |
NASDAQ |
Sep 04, 16:00
267.00
+0.89
(+0.33%)
After-Hours: 20:00
Alnylam Pharmaceuticals SG&A Expense (TTM) : 1.318B for June 30, 2026
SG&A Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical SG&A Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 1.318B |
| March 31, 2026 | 1.293B |
| December 31, 2025 | 1.211B |
| September 30, 2025 | 1.181B |
| June 30, 2025 | 1.080B |
| March 31, 2025 | 1.005B |
| December 31, 2024 | 975.53M |
| September 30, 2024 | 878.31M |
| June 30, 2024 | 856.49M |
| March 31, 2024 | 822.78M |
| December 31, 2023 | 795.65M |
| September 30, 2023 | 807.87M |
| June 30, 2023 | 844.55M |
| March 31, 2023 | 799.85M |
| December 31, 2022 | 770.66M |
| September 30, 2022 | 746.70M |
| June 30, 2022 | 652.91M |
| March 31, 2022 | 628.25M |
| December 31, 2021 | 620.64M |
| September 30, 2021 | 600.55M |
| June 30, 2021 | 625.94M |
| March 31, 2021 | 608.52M |
| December 31, 2020 | 588.42M |
| September 30, 2020 | 578.41M |
| June 30, 2020 | 531.28M |
| Date | Value |
|---|---|
| March 31, 2020 | 516.16M |
| December 31, 2019 | 479.00M |
| September 30, 2019 | 431.42M |
| June 30, 2019 | 427.61M |
| March 31, 2019 | 399.52M |
| December 31, 2018 | 382.36M |
| September 30, 2018 | 341.13M |
| June 30, 2018 | 272.22M |
| March 31, 2018 | 233.32M |
| December 31, 2017 | 199.36M |
| September 30, 2017 | 159.79M |
| June 30, 2017 | 134.53M |
| March 31, 2017 | 106.74M |
| December 31, 2016 | 89.35M |
| September 30, 2016 | 78.71M |
| June 30, 2016 | 72.35M |
| March 31, 2016 | 68.99M |
| December 31, 2015 | 60.61M |
| September 30, 2015 | 57.57M |
| June 30, 2015 | 51.43M |
| March 31, 2015 | 48.32M |
| December 31, 2014 | 44.53M |
| September 30, 2014 | 38.67M |
| June 30, 2014 | 35.54M |
| March 31, 2014 | 29.81M |
SG&A Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (TTM) Benchmarks
| Ionis Pharmaceuticals, Inc. | 527.56M |
| BridgeBio Pharma, Inc. | 645.86M |
| Regeneron Pharmaceuticals, Inc. | 2.743B |
| Vertex Pharmaceuticals, Inc. | 2.008B |
| Pfizer Inc. | 13.72B |